The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -12.98%.However, over the last six months, we can see a weaker performance of 16.51%. Over the last 30 days, the price of GMAB has fallen by 5.12%. And in the last five days, it has surged by 4.68%.
At present, Genmab ADR (GMAB) has a stock price of $22.68. In the previous session, the stock saw a rise, peaking at $46.0 after an opening price of $22.48. The day’s lowest price was $20.0, and it closed at $21.51.
Genmab ADR experienced a rather steady stock market performance.
52-week price history of GMAB Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Genmab ADR’s current trading price is -18.81% away from its 52-week high, while its distance from the 52-week low is 31.62%. The stock’s price range during this period has varied between$17.24 and $27.94. The Genmab ADR’s shares, which operate in the Healthcare, saw a trading volume of around 1.69 million for the day, a figure considerably higher than their average daily volume of 1.37 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Genmab ADR (GMAB) has experienced a quarterly rise of 10.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 13.95B and boasts a workforce of 2682 employees.
Genmab ADR: Analysts’ Ratings Unveiled
As of right now, 4 analysts are rating Genmab ADR as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 3 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 20.81, with a change in price of +1.99. Similarly, Genmab ADR recorded 1,393,937 in trading volume during the last 100 days, posting a change of +9.68%.
GMAB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for GMAB stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
GMAB Stock Stochastic Average
Genmab ADR’s raw stochastic average for the past 50 days is presently 62.31%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 50.40%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 33.78% and 34.10%, respectively.
